Immunic Sees Unusually High Options Volume (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) saw some unusual options trading on Tuesday. Investors bought 2,229 call options on the stock. This represents an increase of approximately 849% compared to the typical daily volume of 235 call options.

Immunic Trading Up 8.1 %

IMUX traded up $0.10 on Tuesday, hitting $1.27. 752,365 shares of the stock traded hands, compared to its average volume of 594,979. The business has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.22. The firm has a market capitalization of $113.95 million, a PE ratio of -1.03 and a beta of 1.89. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. bought a new stake in Immunic in the 4th quarter valued at $37,000. Virtu Financial LLC acquired a new stake in shares of Immunic during the 3rd quarter valued at about $50,000. HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter valued at about $81,000. Barclays PLC acquired a new position in Immunic in the fourth quarter worth about $84,000. Finally, Jane Street Group LLC lifted its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IMUX shares. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research note on Friday, February 21st. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. Finally, William Blair assumed coverage on Immunic in a report on Tuesday. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.